ArticleInfection and drug resistance2025
Antibiotic Use Thresholds for Carbapenem-Resistant Gram-Negative Bacteria: A Nonlinear Time-Series Study.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To study the association between antimicrobial use density (AUD) and carbapenem-resistant gram-negative bacteria (CRGN) detection rate in a Hospital from 2015 to 2023 and to determine the critical threshold for antimicrobial drug use. Methods: The consumption of antibiotics and the detection rates of four CRGN from inpatients were obtained on quarterly. Regression discontinuity design was used to determine the effect of antibiotics on the detection rates of CRGN. Nonlinear time-series analysis with generalized additivity models (GAMs) was applied. A Results: The consumption of antibiotics remained stable from 2015 to 2019, then showed a decreasing trend from the first quarter of 2020 to the first quarter of 2021, subsequently showed a gradual increasing trend from the second quarter of 2021 to the fourth quarter of 2023. The detection rate of carbapenem-resistant Conclusion: AUD is associated with the detection rates of CRGN. To reduce the detection rates of CRGN, we determined thresholds for carbapenems, aminoglycosides, fluoroquinolones, and glycopeptides at 5.82, 0.06, 7.09, and 0.77 Defined Daily Doses (DDDs)/(100 patient-days), respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.